Sayer’s leave went into effect on Sept. 14, 2025. The Dexcom board appointed Jake Leach to serve as interim principal executive officer, in addition to his current duties as president and COO. Leach has already been selected to take the role permanently at the start of 2026 as part of Dexcom’s planned succession process.
Leach has spent 21 years at the company, leading teams responsible for developing multiple generations of continuous glucose monitors CGMs. In 2022, Leach took over as COO at Dexcom, one of the largest diabetes tech companies in the world. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments.
Read more about Dexcom and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Additionally, Dexcom announced that Mark Foletta, the Dexcom board’s lead independent director, was appointed to serve as interim chair during Sayer’s leave. Neither Foletta, nor Leach, will receive additional compensation in connetion with their respective appointments, the SEC filing said.
Dexcom’s CTO Girish Naganathan will speak about the future of connected health at DeviceTalks West, Oct. 15–16, 2025 in Santa Clara, California. Register at West.DeviceTalks.com.
